Results
- Showing results for:
- Reset all filters
Search results
-
Conference paperHuang Y, Ma S-F, Oldham JM, et al., 2024,
Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease
, International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, Pages: 444-454, ISSN: 1073-449X -
Journal articleCalamita E, Liu WH, Ogger PP, et al., 2024,
Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis
, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 210, Pages: 521-523, ISSN: 1073-449X -
Journal articleThillai M, Oldham JM, Ruggiero A, et al., 2024,
Deep Learning-based Segmentation of Computed Tomography Scans Predicts Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis
, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 210, Pages: 465-472, ISSN: 1073-449X -
Journal articleMall MA, Burgel P-R, Castellani C, et al., 2024,
Cystic fibrosis.
, Nat Rev Dis Primers, Vol: 10Cystic fibrosis is a rare genetic disease caused by mutations in CFTR, the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). The discovery of CFTR in 1989 has enabled the unravelling of disease mechanisms and, more recently, the development of CFTR-directed therapeutics that target the underlying molecular defect. The CFTR protein functions as an ion channel that is crucial for correct ion and fluid transport across epithelial cells lining the airways and other organs. Consequently, CFTR dysfunction causes a complex multi-organ disease but, to date, most of the morbidity and mortality in people with cystic fibrosis is due to muco-obstructive lung disease. Cystic fibrosis care has long been limited to treating symptoms using nutritional support, airway clearance techniques and antibiotics to suppress airway infection. The widespread implementation of newborn screening for cystic fibrosis and the introduction of a highly effective triple combination CFTR modulator therapy that has unprecedented clinical benefits in up to 90% of genetically eligible people with cystic fibrosis has fundamentally changed the therapeutic landscape and improved prognosis. However, people with cystic fibrosis who are not eligible based on their CFTR genotype or who live in countries where they do not have access to this breakthrough therapy remain with a high unmet medical need.
-
Journal articleHowlett P, Gan J, Lesosky M, et al., 2024,
Relationship between cumulative silica exposure and silicosis: a systematic review and dose-response meta-analysis
, THORAX, ISSN: 0040-6376 -
Journal articleFeary J, Devaraj A, Burton M, et al., 2024,
Artificial stone silicosis: a UK case series
, THORAX, ISSN: 0040-6376 -
Journal articleKoreshkov M, Antreich SJ, Bismarck A, et al., 2024,
Sustainable food packaging using modified SiO<sub>2</sub> nanofillers in biodegradable polymers
, MATERIALS CHEMISTRY FRONTIERS, Vol: 8, Pages: 2754-2763 -
Journal articleMeldrum OW, Donaldson GC, Narayana JK, et al., 2024,
Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease
, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 210, Pages: 298-310, ISSN: 1073-449X -
Journal articleBlank M, Wilson RC, Wan Y, et al., 2024,
Exploring real-world vancomycin target attainment in neonatal intensive care in the context of Staphylococcal infections: a retrospective observational cohort study
, Journal of Infection, Vol: 89, ISSN: 0163-4453 -
Journal articleJaillais Y, Bayer E, Bergmann DC, et al., 2024,
Guidelines for naming and studying plasma membrane domains in plants
, NATURE PLANTS, Vol: 10, Pages: 1172-1183, ISSN: 2055-026X
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
General enquiries
For any enquiries about the Fungal Science Network at Imperial, please contact: